$830 Million is the total value of BVF INC/IL's 43 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ANAB | Sell | ANAPTYSBIO INC | $59,868,000 | +24.2% | 594,397 | -56.9% | 7.22% | +17.8% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $57,866,000 | -17.5% | 767,354 | -23.8% | 6.98% | -21.8% |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $50,958,000 | +10.2% | 1,969,789 | -37.2% | 6.14% | +4.5% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $23,738,000 | -41.4% | 1,124,483 | -49.6% | 2.86% | -44.4% |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $19,808,000 | +15.1% | 2,623,562 | -12.2% | 2.39% | +9.2% |
| GTXI | Sell | GTX INC DEL | $14,075,000 | +54.5% | 1,107,433 | -0.1% | 1.70% | +46.5% |
| GLYC | Sell | GLYCOMIMETICS INC | $8,353,000 | -81.5% | 497,474 | -84.6% | 1.01% | -82.5% |
| TOCA | Sell | TOCAGEN INC | $5,706,000 | -56.9% | 556,683 | -47.6% | 0.69% | -59.1% |
| ITCI | Sell | INTRA CELLULAR THERAPIES INC | $3,958,000 | -73.6% | 273,350 | -71.2% | 0.48% | -75.0% |
| LOXO | Sell | LOXO ONCOLOGY INC | $369,000 | -98.3% | 4,386 | -98.2% | 0.04% | -98.4% |
| ADRO | Exit | ADURO BIOTECH INC | $0 | – | -184,764 | -100.0% | -0.25% | – |
| Exit | OREXIGEN THERAPEUTICS INCnote 2.750%12/0 | $0 | – | -10,000,000 | -100.0% | -0.61% | – | |
| ZEAL | Exit | ZEALAND PHARMA A Ssponsored adr | $0 | – | -1,000,000 | -100.0% | -2.44% | – |
| OMED | Exit | ONCOMED PHARMACEUTICALS INC | $0 | – | -4,400,289 | -100.0% | -2.53% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -2,820,000 | -100.0% | -5.65% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.